The importance of growth factors for the maintenance of tissue integrity as well as tissue remodelling and their implication in pathological disorders is well established. EGFR (HER1) is a transmembrane protein that consists of an extracellular ligand binding domain, a transmembrane region and an intracellular domain with intrinsic tyrosine kinase activity. 1 Ligand binding activates an intracellular signalling cascade that leads to the activation of the tyrosine kinase activity of EGFR. The EGFR family consists of four members, including HER1/erbB1, HER2/erbB2 or neu, HER3/erbB3 and HER4/erbB4. EGFR is expressed in many epithelial cell types and carcinomas derived thereof and in nonepithelial cells, for instance smooth muscle cells, fibroblasts and nerve cells.
EGFR is known as a central element for signal transduction and diversification. 2 Of particular interest is the fact that overexpression of EGFR and EGFR-family members, like HER2, has been described in human cancers, in particular breast, bladder, colon, glioma, non-small-cell lung, pancreatic, ovarian, gastric, lung, salivary, head and neck tumors.
2, 3 Yasui et al 4, 5 have observed elevated levels of EGFR in advanced gastric carcinomas. Amplification of the EGFR gene has been described as a rare event in gastric carcinomas. [6] [7] [8] Mutations in the EGFR gene have been detected in glioblastomas, breast, ovarian, prostate and lung carcinomas, 9 but so far not in gastric carcinoma. Dysregulation of the EGFR signal transduction pathway is a clinical target for anticancer therapy. 3 Various strategies have been used to inhibit EGFR activity, targeting both extracellular or intracellular receptor components. 10, 11 EGFR immunohistochemical reactivity has been investigated in colonic adenocarcinoma, and a scoring system evaluating EGFR reactivity has been proposed. 12 EGFR positivity at the invasion front showed the strongest correlation with patient survival. 12 The present study was undertaken to investigate EGFR reactivity in gastric carcinoma using an established detection system and a semiquantitative score, and to correlate it with clinical features and patient survival.
Materials and methods

Patient selection
Patients with a diagnosis of gastric adenocarcinoma who had undergone a total gastrectomy in the period from 1982 to 2001 in the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, with available clinical information and follow-up, were considered. CD-F. and DG collected all the clinical information and follow-up. Age at diagnosis, gender, survival time and cause of death were obtained from the charts. A blinded review of all the cases was made by two pathologists (AG-D. and IB) and a diagnosis according to Laurén's classification of gastric adenocarcinoma was rendered. 13 Mexican Mestizo patients with available paraffin material and a morphologic diagnosis of poorly differentiated intestinal, mixed or diffuse-type adenocarcinoma in which UICC staging criteria 14 could be applied, were included.
EGFR immunohistochemistry
A hematoxylin/eosin stained section was obtained for morphologic review and two consecutive sections were mounted on charged slides for immunohistochemistry. Immunostainings for EGFR were performed using the Dako EGFRpharmDx TM assay detection system (Dako Corporation, Carpinteria, CA), which recognizes a 170 kDa transmembrane receptor encoded by the human HER1 gene. The manual staining protocol was precisely followed, and no substitutions were made. After dewaxing in fresh xylene, 100% ethanol, 95% ethanol and 70% ethanol (four baths each), the slides were placed in a humid chamber for proteolytic digestion with proteinase K solution (100 ml for 5 min), and quenching of endogenous peroxidase for 5 min. The primary antibody was incubated for 30 min followed by 30 min incubation with labelled polymer, and DAB localization of the positive cells. Counterstain was made with hematoxylin followed by 10 slide dips in a bath containing 37 mmol/l ammonia water. In every run control slides were included, which were provided to validate the performance of the reagents of the Dako EGFRpharmDx TM assay detection kit. The control slides contained sections of pelleted, formalin-fixed, paraffin-embedded cell line HT-29 with a moderate level of EGFR protein expression (positive control, IHC staining score of the cell pellet is 2.570.5) and of the EGFR negative CAMA-1 cell line (negative control, score 0). 
EGFR Reactivity Evaluation
Results
EGFR Score of Reactivity
The clinicopathological features of 89 Mexican Mestizo patients with gastric cancer are shown in Table 1 . The summarized results of EGFR immunohistochemistry are shown in Table 2 . Of the 89 carcinomas examined, 47 (52.8%) were negative or reactive in o10% of neoplastic cells (score 0). Complete and/or incomplete membrane staining in 410% of neoplastic cells was weak in 17 (19.1%, score 1 þ ), moderate in 16 (18.0%, score 2 þ ) and strong in nine cases (10.1%, score 3 þ , Figure 1 ). The percentage of EGFR reactive cells per case was also evaluated, without considering the staining intensity. A total of 26 cases (29.2%) were completely EGFR negative, 21 cases (23.6%) showed reactivity in o10% of neoplastic cells, 30 cases (33.7%) were reactive in 10-50% of tumor cells and 12 cases (13.5%) were positive in 450% of neoplastic cells. Nerve and muscle cells served as reactive internal control. Normal gastric mucosa showed no EGFR staining. EGFR reactivity frequently showed a striking variability in the tumor tissue. In some cases, only a few tumor cells were highly reactive (score 3 þ ), while the rest of the tumor showed low reactivity or complete absence of EGFR expression ( Figure 1B ).
EGFR Score and its Correlation with Clinicopathological Features and Morphology
The EGFR score was correlated with clinicopathological features and morphology (Table 3) . EGFR score significantly correlated with distant metastases and clinical stage, but not with histotype, perigastric lymph node status or residual disease.
Influence of EGFR Score and Percentage of EGFR Reactive Neoplastic Cells on Survival
The mean and median of the overall patient followup were 21.3. months or 12.0 months, respectively, with a range of 1-173 months and a standard deviation of 28.8 months. The Kaplan-Meier method was used to correlate EGFR score and percentage of reactive neoplastic cells with patient survival. The log-rank test indicates a global P-value of 0.0083. When the percentage of EGFR reactive cells was correlated with patient survival, no EGFR reactivity or reactivity in o10% cells resulted in increased patient survival when compared with EGFR reactivity in 10-50% or 450% cells (Figure 3 ). This trend was observable, although the result did not reach statistical significance (log-rank test: global P-value 0.0688).
Distribution of EGFR Reactive Neoplastic Cells and Association of EGFR Reactivity with Survival
Localization and intensity of reactivity was evaluated for mucosa, submucosa and deeper zones (muscle layer and subserosa). The presence of EGFR reactive cells in the muscle layer or subserosa was significantly associated with a decrease in patient survival (log-rank test: global P-value 0.0004, Figure 4) .
A correlation between EGFR reactivity score, percentage and localization of positive cells, stage, distant metastases and residual disease status with prognosis was investigated by a univariate analysis (Table 4) . EGFR reactivity score was associated with 
Furthermore, a signifcant association with survival was observed for positive neoplastic cells in muscularis or subserosa (P ¼ 0.001), distant metastases (P ¼ 0.0001) and residual disease (P ¼ 0.012). A multivariate analysis using Cox's proportional hazard model revealed that EGFR positive cells in muscularis or subserosa (P ¼ 0.004), distant metastases (P ¼ 0.016) and residual disease (P ¼ 0.039) were significantly correlated with a decrease in survival (Table 4) . EGFR reactive tumor cells in muscularis or subserosa can therefore be considered as an independent prognostic factor.
Kaplan-Meier survival time analysis was used to correlate residual disease status and EGFR score at the same time with patient survival. We decided to compare EGFR score 0/1 þ with EGFR score 2 þ / 3 þ , since there was no significant difference in survival time in patients with EGFR score 0 and 1 þ (Figure 2) . Survival time of patients with R0 resection with EGFR score 0/1 þ was significantly increased when compared with patients with R0 resection and EGFR score 2 þ /3 þ or patients with R1 resection with or without EGFR reactivity (global P-value 0.0003, Figure 5) . A significant increase in survival time was also detected in patients without Figure 6 ). Finally, a significant decrease in survival time was detected in patients with stage III-IV and EGFR score 2 þ /3 þ when compared with patients in stage III-IV with EGFR score 0/1 þ or patients in stage I-II with or without EGFR positive tumor cells (global P-value 0.0015, Figure 7) . A summary of the survival time analyses is shown in Table 5 . Distant metastases combined with EGFR reactivity score (global P-value o0.0001), residual disease status combined with EGFR reactivity score (global P-value 0.0003), and EGFR reactive cells in muscularis or subserosa (global P-value 0.0004) revealed the strongest impact on survival.
Discussion
EGFR and its ligands are frequently overexpressed in human cancers.
2,3 EGFR overexpression may result from gene amplification or mutation, transcriptional abnormalities or autocrine stimulation by enhanced expression of the ligands EGF and TGFa. EGFR plays a critical role in tumor progression by stimulating cell cycle progression, invasion and metastasis. 15 Specific abregation of EGFR results in cell cycle arrest, apoptosis or dedifferentiaton of cancer cells, which makes EGFR a promising target in cancer therapy. Available EGFR-targeted agents block either kinase activity or are monoclonal antibodies that bind the extracellular domain of the receptor, thereby competing with the natural ligands. Therapeutics against EGFR have entered clinical evaluation in malignant diseases. Clinical phase II and III studies with ZD1839 (Iressa), OSI-774 (Tarceva) and Cetuximab (IMC-C225) have been started for several types of cancer, for instance colorectal carcinoma and non-small-cell lung carcinoma. 16 Immunohistochemistry is the standard tool to determine EGFR overexpression and to identify patients who are most likely to benefit from therapy with anti-EGFR monoclonal antibody or kinase inhibitors. Although immunohistochemical Figure 5 Influence of the residual disease status and EGFR score on survival. The log-rank test statistical analysis indicates a P ¼ 0.0003 when the impact of the residual disease status and EGFR score on survival was investigated. s: significant. Figure 6 Influence of the presence of distant metastases and EGFR score on survival. The log-rank test statistical analysis indicates a Pp0.0001 when the impact of the residual disease status on survival was investigated. s: significant. analysis of EGFR expression in paraffin tissues is well established, there is a need to standardize the detection method and the scoring system. Otherwise, different positivity rates may be observed. This is especially critical for EGFR, since both percentage of positive cells as well as staining intensity are evaluated, similar to HER2 staining. In order to achieve the reproducibility and reliability required for a diagnostic test with potential impact on therapy, the Dako EGFRpharmDx TM assay detection system has been developed, and EGFR expression has already been investigated in colonic adenocarcinoma with this kit. 12 In the present study, the Dako EGFRpharmDx TM assay has been used for the first time in gastric carcinoma. EGFR expression was observed in 47.2% of cases in the neoplastic cells, but not in normal gastric mucosa. In other studies, the observed positivity rates were in the range of 34-43%. 4, 14, 15, 17 A significant association was found in the present study between EGFR reactivity score and distant metastases, clinical stage and patient survival. The presence of EGFR reactive cells in the muscle layer and subserosa was associated with a decrease in survival. Intratumoral EGFR expression was very heterogeneous, which indicates that EGFR overexpression might be a late event in tumor progression or might be related to genetic instability.
EGFR as a Prognostic Marker in Gastric Cancer
Our finding that EGFR reactivity score may serve as a prognostic indicator in gastric cancer is in accordance with several studies that have demonstrated that EGFR expression correlates with poor prognosis. 18 Recently, the relationship between EGFR expression and cancer prognosis was investigated based on the analysis of literature data of more than 200 studies published between 1985 and 2000. 18 It was found that EGFR expression was a strong prognostic indicator in cancers of the head and neck, ovary, cervix, bladder and esophagus, and that EGFR expression correlated with reduced recurrence-free and overall survival in 70% of studies included in the literature search. In gastric, breast, endometrial and colorectal cancers, EGFR expression was associated with poor survival in 52% of the included studies, while in non-small-cell lung cancer only 30% of studies showed such a correlation between EGFR expression and survival. The variations of the results between the different studies might be due to different methodical setups and further point to a need of a standardized EGFR immunohistochemistry. For gastric cancer, co-expression of EGFR and its ligands EGF or TGF-a was found to be correlated with a decrease of survival or the relapse-free survival interval. 4, 17, 19 Amplification 7, 8 or expression of EGFR 4 was correlated with advanced clinical stage and the presence of lymph node metastasis.
5,20
EGFR Positivity in Muscle Layer or Subserosa
In the present study, the presence and staining intensity of EGFR reactive cells were evaluated in mucosa, submucosa and at the deep invasion front in muscle layer and subserosa after exclusion of two patients with early cancer in muscosa and submucosa. The localization of EGFR reactive cells in muscle layer and subserosa was associated with a decrease in patient survival which indicates that EGFR positivity at the deep invasion front is critical in determining the patient's outcome. In a recent study using the same technique in colonic adenocarcinoma, positivity at the invasion front also showed the strongest correlation with survival duration as well as with EGFR positivity of lymph node and liver metastases. 12 Increased EGFR expression at the most invasive parts of carcinomas has also been reported for oral squamous cell carcinomas. 21 These data support the hypothesis that the invasive front of carcinomas is the most critical area for prognostication. 12, 22, 23 Heterogeneity of EGFR Expression EGFR reactivity showed a marked intratumoral heterogeneity, frequently showing a range of completely negative up to 3 þ positive neoplastic cells within an individual case. EGFR staining heterogeneity was also observed for colonic adenocarcinoma. 12 These observations argue for an upregulation of EGFR expression in later stages of tumor progression. Different mechanisms, like autocrine stimulation by growth factors, genetic instability or transcriptional deregulation, may be considered. Amplification of the EGFR gene has been described in gastric carcinomas, [6] [7] [8] but no mutations have been found so far. 9 With regard to anti-EGFR therapy, the impact of EGFR heterogeneity on the therapeutic response has to be clarified. It may also be of importance in the evaluation of small tumor samples, for example, pretherapeutic endoscopic samples.
Geographic Influence
Our study is the first study that investigates EGFR in tumor samples of Mexican gastric carcinoma patients while other studies frequently investigated samples of Japanese, 4, 5, 7, 8, 17, 19, 20 Northern American 24 or European 25,26-30 gastric carcinoma patients. Although Mexico is a country with a higher incidence of gastric cancer compared to most Western countries, the distribution of histologic subtypes is similar. 31 Overall, our study of Mexican patients produced similar results in terms of incidence and prognostic influence of EGFR expression and lack of correlation with histologic features as studies with other ethnic groups, 25 suggesting that the ethnic and geographic origin of patients is unlikely to play a role in EGFR expression.
Tumor progression to an invasive state includes up-regulation of cellular motility, and EGFR is frequently involved in this process, 32, 33 Anti-EGFRbased therapies aim to interfere with tumor invasion and metastasis. A standardized EGFR scoring system is a prerequiste to define patient subgroups who are likely to benefit from anti-EGFR therapy.
